Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-MY PET Imaging in Solid Tumors
NCT07589101Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-MY in solid tumor, lung cancer and breast cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Radiation Dosimetry of 68Ga-MY at 14 days, Standardized Uptake Value at 14 days and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
68Ga-MY
03
Conditions
solid tumorlung cancerbreast cancer
Beyond the preview
Go deeper on NCT07589101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589101.